Genaera Corporation

Ligand Pharmaceuticals, Inc.

Jamila Louahed

Nicholas C Nicolaides

Roy Clifford Levitt

Yuhong Zhou

W Lee Maloy

Kenneth J Holroyd

Mike McLane

Qu Dong

Michael McLane

The present invention is drawn to methods for modulating IL-13 expression and/or activity in a mammal comprising administering an effective amount of an agent which modulates the expression and/or activity of IL-9.

Methods for the modulation of IL-13

A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.

Methods for treating ICACC protein associated diseases

Nucleic acids encoding a chloride channel protein

A new gene in the calcium-activated chloride channel family has been discovered that is induced by L-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered.

Methods for identification of agents which modulate chloride channel activity

Growing community of inventors

Plymouth Meeting, PA, United States of America

Jamila Louahed